{
    "clinical_study": {
        "@rank": "119300", 
        "acronym": "PHARO", 
        "arm_group": {
            "arm_group_label": "Patient", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Laryngopharyngeal reflux (LPR) is the retrograde movement of gastric contents into the\n      larynx, pharynx and upper aerodigestive tract. The symptoms and manifestations are very\n      changeable and non specific. Pharyngeal and Oesophageal pH-impedance may help to detect\n      these reflux and to identify patients with abnormal LPR.\n\n      To compare and describe the results of pharyngeal and oesophageal pH-impedance of patients\n      with high suspicion of laryngopharyngeal reflux, with the results of healthy patients."
        }, 
        "brief_title": "Benefit of Pharyngeal and Oesophageal pH-impedance of Patients With High Suspicion of Laryngopharyngeal Reflux", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Laryngopharyngeal Reflux", 
            "Oesophageal pH-impedance"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Gastroesophageal Reflux", 
                "Regurgitation, Gastric"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a monocentric, prospective descriptive study. Patients will be recruited in\n      otolaryngology and gastroenterology departments of Bordeaux teaching hospital. A first\n      clinical, endoscopic and pH-impedance evaluation will be made, after at least 15 days of\n      interruption of any proton pump inhibitors (PPI). After 8 weeks' treatment by double PPI\n      doses (esomeprazole 40 mg bid), another clinical and pH-impedance evaluation will be\n      realized. The characteristics of the patients who respond to the  treatment will be compared\n      to non responders. The subjects will also have an initial laryngoscopy, an oesophageal\n      manometry allowing the location of the lower sphincter of the oesophagus and the upper\n      sphincter of the oesophagus for positioning the catheters."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  age : 18 to 80 years old.\n\n          -  Written consent\n\n          -  Laryngopharyngeal symptoms (dysphonia, and/or globus and/or sensation, and/or\n             pharyngeal pain, and/or cough) for 3 months at least.\n\n          -  No PPI for at least 15 days\n\n          -  Social security affiliation\n\n        Exclusion Criteria:\n\n          -  Sinusitis or chronic rhinitis  (in the previous year)\n\n          -  Laryngeal trauma, tracheotomy or pharyngolaryngeal surgery\n\n          -  pregnancy or absence of efficacy contraception\n\n          -  breast feeding\n\n          -  history of gastrointestinal pathology,  diabetes, neurological condition\n\n          -  cardio-vascular history requiring the taking of Plavix\n\n          -  esomeprazole contraindication or intolerance"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01854970", 
            "org_study_id": "CHUBX 2012/08"
        }, 
        "intervention": {
            "arm_group_label": "Patient", 
            "description": "Patients with pharyngolaryngeal symptoms will have a clinical evaluation, laryngoscopy, and pharyngoesophageal pH-impedance. Then a treatment by esomeprazole during 8 weeks in the term of which the second clinical evaluation and pH-impedance will be made.", 
            "intervention_name": "esomeprazole", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 1, 2014", 
        "location": {
            "contact": {
                "email": "amandine.lechot@chu-bordeaux.fr", 
                "last_name": "Amandine LECHOT, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Bordeaux", 
                    "country": "France", 
                    "zip": "33000"
                }, 
                "name": "CHU de Bordeaux"
            }, 
            "investigator": [
                {
                    "last_name": "Amandine LECHOT, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Frank ZERBIB, Prof", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Benefit of Pharyngeal and Oesophageal pH-impedance of Patients With High Suspicion of Laryngopharyngeal Reflux", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of pharyngeal reflux/24h", 
                "safety_issue": "No", 
                "time_frame": "visit 3 - 60 days after inclusion"
            }, 
            {
                "measure": "\u2022 Number of pharyngeal acid reflux/24h", 
                "safety_issue": "No", 
                "time_frame": "Visit 3 - 60 days after inclusion"
            }, 
            {
                "measure": "\u2022 Number of pharyngeal less acid reflux/24h", 
                "safety_issue": "No", 
                "time_frame": "Visit 3 - 60 days after inclusion"
            }, 
            {
                "measure": "\u2022 Pharyngeal acid exposure (% of total time with  pharyngeal pH <4)", 
                "safety_issue": "No", 
                "time_frame": "Visit 3 - 60 days after inclusion"
            }, 
            {
                "measure": "\u2022 Pharyngeal bolus exposure (% of total time with liquid in the pharynx)", 
                "safety_issue": "No", 
                "time_frame": "Visit 3 - 60 days after inclusion"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01854970"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University Hospital, Bordeaux", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Hospital, Bordeaux", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}